Business Wire

AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases

CAMBRIDGE, Mass. & TÜBINGEN, Germany--(BUSINESS WIRE)--AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today emerged from ...
Business Wire

AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic

CAMBRIDGE, Mass. & TÜBINGEN, Germany--(BUSINESS WIRE)--AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the ...
Seeking Alpha

SOHM Announces Its Acquisition of ABBIE, a World-Class Gene-Editing Platform Which Can Deliver Genetic Payloads Using Non-Viral Vectors

CHINO HILLS, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering ...
Yahoo Finance

AIRNA Announces First Patient Dosed in Phase 1 Trial of AIR-001, Potential Best-in-Class RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

CAMBRIDGE, Mass., April 07, 2026--(BUSINESS WIRE)--AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, today announced the ...
Benzinga.com

Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating

Korro Bio's lead asset is expected to enter a Phase 1/2 trial in adult A1ATD patients in the second half of 2024. Analyst writes Korro's preclinical data package, particularly in the NSG PiZ mouse ...
Nasdaq

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...